Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Sara Elena RebuzziAlessio SignoriGiuseppe Luigi BannaMaruzzo MarcoUgo De GiorgiPaolo PedrazzoliAndrea SbranaPaolo Andrea ZucaliCristina MasiniEmanuele NaglieriGiuseppe ProcopioSara MerlerLaura TomaselloLucia FratinoCinzia BaldessariRiccardo RicottaStefano PanniVeronica MollicaMaria SorarùMatteo SantoniAlessio CortelliniVeronica PratiHector Josè Soto ParraMarco StellatoFrancesco AtzoriSandro PignataCarlo MessinaMarco MessinaFranco MorelliGiuseppe PratiFranco NolèFrancesca VignaniAlessia CavoGiandomenico RovielloFrancesco PierantoniChiara CasadeiMelissa BersanelliSilvia ChiellinoFederico PaolieriMatteo PerrinoMatteo BrunelliRoberto IacovelliCamillo PortaSebastiano ButiGiuseppe FornariniPublished in: Therapeutic advances in medical oncology (2021)
The Meet-URO score allowed for the accurate stratification of pretreated mRCC patients receiving nivolumab and is easily applicable for clinical practice at no additional cost. Future steps include its external validation, the assessment of its predictivity, and its application to first-line combinations.